logo
Plus   Neg
Share
Email

AstraZeneca Announces Approval For Tagrisso In China - Quick Facts

AstraZeneca (AZN.L,AZN) said Tagrisso has received marketing authorisation in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer. The company said the approval from China's National Medical Products Administration followed the Priority Review Pathway and is based on results from the Phase III FLAURA trial.

Tagrisso was approved in China in 2017 and added to the National Reimbursement Drug List effective from January 2019 for the 2nd-line treatment of adult patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in... Google parent Alphabet Inc. has issued $5.75 billion in sustainability bonds, becoming the largest green or sustainability bonds issued by a company until now. This is part of a $10 billion debt offering. Alphabet said the proceeds will be used to fund projects that are environmentally or socially responsible.
Follow RTT